77898-24-9

Basic information

• Product Name: 3-chloro-4-fluoro-N-methylaniline
• Synonyms: 3-chloro-4-fluoro-N-methylaniline
• CAS NO: 77898-24-9
• Molecular Weight: 159.591
• Mol File: 77898-24-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-chloro-4-fluoro-N-methylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-4-fluoro-N-methylaniline(77898-24-9)
• EPA Substance Registry System: 3-chloro-4-fluoro-N-methylaniline(77898-24-9)

Safety Data

• Hazardous Substances Data: 77898-24-9(Hazardous Substances Data)

Upstream product

• 119951-96-1 (3-chloro-4-fluoro-phenyl)-carbamic acid tert-butyl ester 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 770-22-9 N-(3-chloro-4-fluoro-phenyl)-formamide 
• 297150-27-7 C₁₃H₁₀ClFN₄ 

Downstream Products

• 1240693-60-0 C₁₇H₁₀ClF₂N₃ 

Relevant articles and documents

Evaluation of 4-phenylamino-substituted naphthalene-1,2-diones as tubulin polymerization inhibitors

A series of 4-phenylamino-substituted naphthalene-1,2-dione derivatives were prepared and evaluated as effective antiproliferative agents. MTT assays showed that the compounds with a methyl group on the nitrogen linker exhibited potent antiproliferative activities against human cancer cells. The mechanistic study revealed that these compounds could induce mitochondrial depolarization, which resulted in intracellular ROS production, and they also acted as tubulin polymerization inhibitors. Moreover, the typical compound could arrest A549 cells in the G2/M phase, resulting in cellular apoptosis and induced mitotic arrest in A549 cells through disrupting microtubule dynamics.

AMINONITRILES AS KYNURENINE PATHWAY INHIBITORS

The present application provides novel kynurenine pathway inhibitors and pharmaceutically acceptable salts and prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in regulating the kynurenine pathway and the activity of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase by administering a therapeutically effective amount of one or more of the compounds of formula (I) to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the kynurenine pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by immunosuppression, abnormal cellular proliferation and/or inflammation. In one embodiment, the disease is cancer. In another embodiment, the disease is a viral infection. In a further embodiment, the disease is depression.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.